138 related articles for article (PubMed ID: 35904290)
21. Comparison of analgesic and anti-inflammatory activity of meloxicam gel with diclofenac and piroxicam gels in animal models: pharmacokinetic parameters after topical application.
Gupta SK; Bansal P; Bhardwaj RK; Jaiswal J; Velpandian T
Skin Pharmacol Appl Skin Physiol; 2002; 15(2):105-11. PubMed ID: 11867967
[TBL] [Abstract][Full Text] [Related]
22. Meloxicam.
Khalil NY; Aldosari KF
Profiles Drug Subst Excip Relat Methodol; 2020; 45():159-197. PubMed ID: 32164967
[TBL] [Abstract][Full Text] [Related]
23. Meloxicam in rheumatoid arthritis.
Ahmed M; Khanna D; Furst DE
Expert Opin Drug Metab Toxicol; 2005 Dec; 1(4):739-51. PubMed ID: 16863437
[TBL] [Abstract][Full Text] [Related]
24. Blood Glutathione Peroxidase Activity in Patients with Osteoarthritis Treated with Oxicams.
Amzoiu DC; Pisoschi CG; Stoian Bulearcă AM; Rău G
Curr Health Sci J; 2016; 42(1):29-34. PubMed ID: 30568809
[TBL] [Abstract][Full Text] [Related]
25. Effect of lipid molecule headgroup mismatch on non steroidal anti-inflammatory drugs induced membrane fusion.
Mondal Roy S; Sarkar M
Langmuir; 2011 Dec; 27(24):15054-64. PubMed ID: 21999838
[TBL] [Abstract][Full Text] [Related]
26. Synthesis, COX-1/2 inhibition and antioxidant activities of new oxicam analogues designed as potential chemopreventive agents.
Szczęśniak-Sięga B; Gębczak K; Gębarowski T; Maniewska J
Acta Biochim Pol; 2018; 65(2):199-207. PubMed ID: 29906298
[TBL] [Abstract][Full Text] [Related]
27. Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam.
Tavakoli M
Pharmacoeconomics; 2003; 21(6):443-54. PubMed ID: 12678570
[TBL] [Abstract][Full Text] [Related]
28. Clinical pharmacokinetics of lornoxicam. A short half-life oxicam.
Skjodt NM; Davies NM
Clin Pharmacokinet; 1998 Jun; 34(6):421-8. PubMed ID: 9646006
[TBL] [Abstract][Full Text] [Related]
29. Incorporation of NSAIDs in micelles: implication of structural switchover in drug-membrane interaction.
Chakraborty H; Banerjee R; Sarkar M
Biophys Chem; 2003 May; 104(1):315-25. PubMed ID: 12834850
[TBL] [Abstract][Full Text] [Related]
30. Piroxicam-induced photodermatitis. Cross-reactivity among oxicams. A case report.
Trujillo MJ; de Barrio M; Rodríguez A; Moreno-Zazo M; Sánchez I; Pelta R; Tornero P; Herrero T
Allergol Immunopathol (Madr); 2001; 29(4):133-6. PubMed ID: 11674927
[TBL] [Abstract][Full Text] [Related]
31. Effects of oxicam inhibitors of cyclooxygenase on oxidative stress generation in rat gastric mucosa. A comparative study.
Villegas I; Martín MJ; La Casa C; Motilva V; De La Lastra CA
Free Radic Res; 2002 Jul; 36(7):769-77. PubMed ID: 12180128
[TBL] [Abstract][Full Text] [Related]
32. Comparative biochemical pharmacology of the oxicams.
Fenner H
Scand J Rheumatol Suppl; 1987; 65():97-101. PubMed ID: 3500509
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1.
Ogino K; Hatanaka K; Kawamura M; Katori M; Harada Y
Pharmacology; 1997 Jul; 55(1):44-53. PubMed ID: 9309800
[TBL] [Abstract][Full Text] [Related]
34. Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial.
Dougados M; Gueguen A; Nakache JP; Velicitat P; Veys EM; Zeidler H; Calin A
Rheumatology (Oxford); 1999 Mar; 38(3):235-44. PubMed ID: 10325662
[TBL] [Abstract][Full Text] [Related]
35. Effects of non-steroid anti-inflammatory drugs in membrane bilayers.
Kyrikou I; Hadjikakou SK; Kovala-Demertzi D; Viras K; Mavromoustakos T
Chem Phys Lipids; 2004 Dec; 132(2):157-69. PubMed ID: 15555602
[TBL] [Abstract][Full Text] [Related]
36. Meloxicam.
Noble S; Balfour JA
Drugs; 1996 Mar; 51(3):424-30; discussion 431-32. PubMed ID: 8882380
[TBL] [Abstract][Full Text] [Related]
37. Anti-Inflammatory Oxicams as Multi-donor Ligand Systems: pH- and Solvent-Dependent Coordination Modes of Meloxicam and Piroxicam to Ru and Os.
Aman F; Hanif M; Kubanik M; Ashraf A; Söhnel T; Jamieson SM; Siddiqui WA; Hartinger CG
Chemistry; 2017 Apr; 23(20):4893-4902. PubMed ID: 28198061
[TBL] [Abstract][Full Text] [Related]
38. Oxicam structure in non-steroidal anti-inflammatory drugs is essential to exhibit Akt-mediated neuroprotection against 1-methyl-4-phenyl pyridinium-induced cytotoxicity.
Tasaki Y; Yamamoto J; Omura T; Noda T; Kamiyama N; Yoshida K; Satomi M; Sakaguchi T; Asari M; Ohkubo T; Shimizu K; Matsubara K
Eur J Pharmacol; 2012 Feb; 676(1-3):57-63. PubMed ID: 22182582
[TBL] [Abstract][Full Text] [Related]
39. Tenoxicam. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
Gonzalez JP; Todd PA
Drugs; 1987 Sep; 34(3):289-310. PubMed ID: 3315620
[TBL] [Abstract][Full Text] [Related]
40. Meloxicam.
Fleischmann R; Iqbal I; Slobodin G
Expert Opin Pharmacother; 2002 Oct; 3(10):1501-12. PubMed ID: 12387696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
